Sejal Patel
Columbia, SCNPI 1679673156
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $892 of the $971 with a category attached, or 91.9%. Eli Lilly accounts for 91.9% of it on its own, with 2 other manufacturers making up the rest.
Across 5 payments — averaging $194.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$892
- AbbVie$59
- Merck$20
Across 308 payments — averaging $4616.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$605K
- Janssen Research & Development, LLC$408K
- Boehringer Ingelheim International GmbH$217K
- Eli Lilly$166K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$27K
What the payments were for
- Travel & lodging$89292%
- Food & beverage$798%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.